Apellis Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Apellis Pharmaceuticals, Inc.‘s stocks are currently a part of 225 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 91.57M shares of Apellis Pharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 0.97% or 882.21K shares more. As for the holding position changes, 37.33% (84) of current hedge fund investors increased the number of shares held, 26.67% (60) of current holders sold a part of the shares held, and 10.22% (23) closed the holdings completely. 60 hedge funds are new holders of Apellis Pharmaceuticals, Inc. stock in Q3 2022, it is 26.67% of total holders.
Hedge funds holding Apellis Pharmaceuticals (Q4 2017 – Q3 2022)
| Q4 2017 | 47 |
|---|---|
| Q1 2018 | 47 |
| Q2 2018 | 74 |
| Q3 2018 | 80 |
| Q4 2018 | 96 |
| Q1 2019 | 92 |
| Q2 2019 | 98 |
| Q3 2019 | 131 |
| Q4 2019 | 134 |
| Q1 2020 | 144 |
| Q2 2020 | 142 |
| Q3 2020 | 142 |
| Q4 2020 | 166 |
| Q1 2021 | 172 |
| Q2 2021 | 201 |
| Q3 2021 | 176 |
| Q4 2021 | 183 |
| Q1 2022 | 205 |
| Q2 2022 | 204 |
| Q3 2022 | 225 |
Hedge funds changes in Apellis Pharmaceuticals positions (Q4 2017 – Q3 2022)
| Q4 2017 | 47 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|
| Q1 2018 | 10 | 17 | 10 | 10 | 0 |
| Q2 2018 | 35 | 31 | 5 | 8 | -5 |
| Q3 2018 | 12 | 34 | 22 | 6 | 6 |
| Q4 2018 | 27 | 34 | 26 | 11 | -2 |
| Q1 2019 | 14 | 35 | 28 | 17 | -2 |
| Q2 2019 | 21 | 45 | 20 | 12 | 0 |
| Q3 2019 | 45 | 46 | 28 | 11 | 1 |
| Q4 2019 | 33 | 50 | 37 | 25 | -11 |
| Q1 2020 | 35 | 62 | 35 | 23 | -11 |
| Q2 2020 | 15 | 73 | 36 | 15 | 3 |
| Q3 2020 | 21 | 50 | 47 | 21 | 3 |
| Q4 2020 | 37 | 50 | 59 | 13 | 7 |
| Q1 2021 | 28 | 53 | 61 | 21 | 9 |
| Q2 2021 | 51 | 72 | 57 | 21 | 0 |
| Q3 2021 | 30 | 79 | 51 | 52 | -36 |
| Q4 2021 | 44 | 71 | 53 | 35 | -20 |
| Q1 2022 | 52 | 72 | 61 | 27 | -7 |
| Q2 2022 | 31 | 97 | 54 | 29 | -7 |
| Q3 2022 | 60 | 84 | 60 | 23 | -2 |
Hedge funds changes in Apellis Pharmaceuticals stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 0 | 0 |
|---|---|---|
| Q1 2018 | 0 | 0 |
| Q2 2018 | 0 | 0 |
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 1,463,000 | 1,463,000 |
| Q2 2019 | 1,906,000 | 1,901,000 |
| Q3 2019 | 9,030,000 | 462,000 |
| Q4 2019 | 43,057,000 | 36,043,000 |
| Q1 2020 | 5,345,000 | 11,406,000 |
| Q2 2020 | 8,237,000 | 6,759,000 |
| Q3 2020 | 7,739,000 | 3,671,000 |
| Q4 2020 | 16,315,000 | 6,955,000 |
| Q1 2021 | 24,052,000 | 7,553,000 |
| Q2 2021 | 134,778,000 | 91,797,000 |
| Q3 2021 | 142,916,000 | 146,739,000 |
| Q4 2021 | 44,292,000 | 23,748,000 |
| Q1 2022 | 82,935,000 | 82,823,000 |
| Q2 2022 | 56,158,000 | 22,272,000 |
| Q3 2022 | 67,770,000 | 103,116,000 |